Skip to content

Lifestyle and dietary management

TL;DR — Lifestyle interventions lower blood pressure by amounts comparable to single drugs, and one of them now has hard-endpoint evidence. Salt substitution (75% NaCl / 25% KCl) in 20,995 rural Chinese adults cut stroke (rate ratio 0.86, 95% CI 0.77–0.96), major cardiovascular events (0.87, 0.80–0.94) and all-cause death (0.88, 0.82–0.95) over 4.74 years without excess hyperkalaemia events (Neal 2021, PMID 34459569) — the only lifestyle intervention in hypertension with a positive mortality trial. Sodium reduction has a clean dose–response: each 50 mmol/day reduction in 24-hour urinary sodium lowered systolic pressure 1.10 mm Hg (95% CI 0.66–1.54) across 133 trials and 12,197 participants, with larger effects in older, non-white and higher-pressure people, and short trials underestimating the effect by more than half (Huang 2020, PMID 32094151). DASH plus low sodium reduced systolic pressure 11.5 mm Hg below the control-plus-high-sodium condition in hypertensive participants (Sacks 2001, PMID 11136953). The persistent problems are durability outside feeding studies and a genuine, unresolved observational dispute about whether very low sodium intake is harmful (O'Donnell 2014, PMID 25119607).

Effect sizes at a glance

Intervention Systolic effect Population Source
DASH diet (feeding study) −11.4 mm Hg vs control in hypertensive participants; −3.5 in normotensive 459 adults (Appel 1997, PMID 9099655)
DASH + low sodium vs control + high sodium −11.5 mm Hg in hypertensive; −7.1 in non-hypertensive 412 adults (Sacks 2001, PMID 11136953)
Sodium reduction, per 50 mmol/day −1.10 mm Hg (95% CI 0.66–1.54) 133 trials, 12,197 participants (Huang 2020, PMID 32094151)
Sodium reduction, overall trial contrast −4.26 mm Hg (3.62–4.89) for a 130 mmol/day reduction Same (Huang 2020, PMID 32094151)
Salt substitute −4.61 mm Hg (95% CI −6.07 to −3.14) systolic; −1.61 (−2.42 to −0.79) diastolic 21 trials, 31,949 participants (Yin 2022, PMID 35945000)
Potassium supplementation U-shaped; benefit weakens above ~30 mmol/day difference and reverses above ~80 mmol/day 32 trials (Filippini 2020, PMID 32500831)
Alcohol reduction (≥6 drinks/day, halved) −5.50 mm Hg (95% CI −6.70 to −4.30) 36 trials, 2,865 participants (Roerecke 2017, PMID 29253389)
Exercise vs control Comparable to individual antihypertensive classes in hypertensive populations 197 exercise + 194 drug RCTs (Naci 2019, PMID 30563873)
DASH in network meta-analysis of 22 non-drug interventions −6.97 mm Hg (95% CrI 4.50–9.47), ranked first 120 trials, 14,923 participants (Fu 2020, PMID 32975166)
Weight-reducing diets, long term Modest and attenuating Cochrane (Semlitsch 2021, PMID 33555049)

Sodium

The trial evidence is dose-responsive and durable. Huang's meta-analysis of 133 randomised trials with 24-hour urinary sodium verification found a mean reduction of 130 mmol/day producing −4.26 mm Hg systolic (95% CI 3.62–4.89) and −2.07 diastolic (1.67–2.48). Per 50 mmol/day: −1.10 mm Hg systolic. Crucially, trials shorter than 15 days showed less than half the effect of longer trials (−1.05 vs −2.13 mm Hg per 50 mmol), so the short-trial literature systematically understates the effect (Huang 2020, PMID 32094151). Older Cochrane work established the same direction (He 2013, PMID 23633321; He 2002, PMID 12444537), and baseline potassium intake modifies the sodium–pressure slope (Huang 2021, PMID 33674705).

The observational evidence is contested. In PURE, estimated 24-hour sodium excretion below 3 g/day was associated with higher risk of death and major cardiovascular events (OR 1.27, 95% CI 1.12–1.44) than the 4–6 g/day reference, as was excretion ≥7 g/day (OR 1.15, 1.02–1.30), producing a J-shape (O'Donnell 2014, PMID 25119607). Pooled analyses from the same group reported that high sodium was associated with cardiovascular events only in hypertensive individuals (Mente 2016, PMID 27216139), and joint sodium–potassium analyses reinforce the potassium limb (O'Donnell 2019, PMID 30867146). The counter-argument is methodological: spot-urine-based estimating equations misclassify intake, and reverse causation from illness lowers intake. Chinese cohort data give a different shape again (Liu 2021, PMID 33031177), and umbrella reviews summarise the standoff without resolving it (Kong 2025, PMID 41243115). This is an unresolved contradiction in the literature, and it is content, not a defect — it is the single largest unsettled question in preventive nutrition for hypertension.

Population-level sodium reduction through reformulation and labelling is a separate evidence base with its own limitations (McLaren 2016, PMID 27633834; Song 2021, PMID 34610024). In chronic kidney disease, altered salt intake has been reviewed specifically (McMahon 2021, PMID 34164803; Borrelli 2020, PMID 32635265).

Salt substitution — the hard-endpoint exception

SSaSS cluster-randomised 600 Chinese villages (20,995 participants; 72.6% with prior stroke, mean age 65.4) to 75% NaCl / 25% KCl versus regular salt. Over a mean 4.74 years: stroke 29.14 vs 33.65 per 1,000 person-years (RR 0.86, 95% CI 0.77–0.96, p=0.006), major cardiovascular events 49.09 vs 56.29 (0.87, 0.80–0.94), death 39.28 vs 44.61 (0.88, 0.82–0.95); hyperkalaemia-attributed serious adverse events 3.35 vs 3.30 per 1,000 person-years (RR 1.04, 0.80–1.37) (Neal 2021, PMID 34459569). Interim data confirmed the mechanism was blood-pressure-mediated (Huang 2020, PMID 31986290), and secondary analyses cover cardiac outcomes, fractures, gastric cancer and recurrent stroke (Yu 2024, PMID 38465623; Wang 2024, PMID 39232779; Zhang 2025, PMID 40264179; Ding 2025, PMID 39908026).

Generalisability is the question. Meta-analysis of 21 trials across geographies found consistent pressure reduction with no heterogeneity by region, age, sex, hypertension history, BMI or baseline urinary sodium or potassium, and a dose–response by substitution fraction: each 10% lower sodium chloride content gave an additional −1.53 mm Hg systolic (95% CI −3.02 to −0.03) (Yin 2022, PMID 35945000). Clinical-outcome meta-analysis reaches the same conclusion (Tsai 2022, PMID 36196475), and a Cochrane review covers adults, children and pregnant women (Brand 2022, PMID 35944931). The unresolved issue is safety in people with chronic kidney disease or on renin-angiotensin blockade and potassium-sparing agents, who were largely excluded — SSaSS enrolled a population where most cooking salt is added at home, which is not the pattern in high-income countries where most sodium is embedded in processed food.

Dietary pattern

DASH remains the strongest non-sodium dietary intervention: −11.4/−5.5 mm Hg versus control in hypertensive participants under weight- and sodium-controlled feeding (Appel 1997, PMID 9099655), replicated in meta-analysis outside feeding conditions (Filippou 2020, PMID 32330233; Guo 2021, PMID 34557511) and associated with lower incident hypertension in cohorts (Theodoridis 2023, PMID 37513679). In network meta-analysis of 22 non-pharmacological interventions, DASH ranked first for both systolic (−6.97 mm Hg, 95% CrI 4.50–9.47) and diastolic pressure (Fu 2020, PMID 32975166).

DASH4D extends this to type 2 diabetes: a four-period crossover feeding trial in 102 adults (87% Black, 66% on ≥2 antihypertensives) found the DASH4D-plus-low-sodium diet reduced systolic pressure 4.6 mm Hg (95% CI 2.0–7.2) and diastolic 2.3 mm Hg versus the comparison-plus-high-sodium diet, with most of the effect attributable to sodium reduction rather than the dietary pattern, and most of it realised within three weeks (Pilla 2025, PMID 40489102). Head-to-head DASH-versus-Mediterranean comparison on a salt-restricted background found both effective (Filippou 2023, PMID 37625311; Filippou 2022, PMID 35092228). General dietary advice, by contrast, has small effects (Rees 2013, PMID 24318424).

Potassium

Potassium supplementation lowers blood pressure, but not monotonically. Cubic-spline modelling of 32 trials found a U-shaped relationship: the pressure-lowering effect weakened above a 30 mmol/day difference in excretion and reversed above roughly 80 mmol/day, with the increase seen in drug-treated but not untreated hypertensive participants; effects were larger at higher sodium intake (Filippini 2020, PMID 32500831). Earlier meta-analyses reported straightforward benefit (Whelton 1997, PMID 9168293; Cappuccio 1991, PMID 1649867; Filippini 2017, PMID 28024910; Binia 2015, PMID 26039623), and recent dose-response updates continue to refine the curve (Granal 2025, PMID 40612568). The practical implication is that potassium is best increased through diet or salt substitution rather than high-dose supplementation, particularly in people on renin-angiotensin blockade.

Alcohol

The dose–response has an apparent threshold. Across 36 trials and 2,865 participants, reduction produced no significant pressure fall in people drinking two or fewer drinks per day; in those drinking six or more per day who halved intake, systolic pressure fell 5.50 mm Hg (95% CI 4.30–6.70) and diastolic 3.97 mm Hg (3.25–4.70) (Roerecke 2017, PMID 29253389). Older trial-level meta-analysis found a smaller overall effect (Xin 2001, PMID 11711507); mechanistic reviews cover the pressor pathways (Fuchs 2021, PMID 34762198).

Physical activity

Network meta-analysis of 391 randomised trials — 197 exercise (10,461 participants) and 194 drug (29,281) — found that medications achieved larger systolic reductions than exercise across all populations (mean difference −3.96 mm Hg, 95% CrI −5.02 to −2.91), but among hypertensive populations specifically there was no detectable difference between endurance or dynamic resistance exercise and ACE inhibitors, ARBs, β-blockers or diuretics. Only 56 exercise trials (3,508 individuals) enrolled hypertensive participants, and risk of bias was higher in exercise trials, so the comparison is underpowered rather than settled (Naci 2019, PMID 30563873). Earlier syntheses established endurance training's effect (Cornelissen 2013, PMID 23525435), and isometric resistance training has the largest per-session effect in several meta-analyses (Carlson 2014, PMID 24582191; Baffour-Awuah 2023, PMID 36853479).

Weight

Long-term weight-reducing diets lower blood pressure modestly, with attenuation over time (Semlitsch 2021, PMID 33555049); low-calorie diet plus exercise outperformed exercise alone in overweight and obese participants in network meta-analysis (Fu 2020, PMID 32975166). Incretin-based pharmacotherapy has substantially changed the achievable weight loss and produces blood-pressure reduction as a secondary effect (Ansari 2024, PMID 38029929; Yin 2025, PMID 40207414; Elmaleh-Sachs 2023, PMID 38015216; McGowan 2025, PMID 41039116) — this belongs to obesity management rather than hypertension therapy, but it materially changes what "weight loss" means as a blood-pressure intervention. The 2026 AHA/ACC/ADA/ASN cardiovascular-kidney-metabolic guideline formalises the overlap (Ndumele 2026, PMID 42265997).

Stress reduction and breathing

Meditation, breathing control and relaxation appear in network meta-analysis with moderate-to-high-quality evidence of modest effect (Fu 2020, PMID 32975166), and a dedicated systematic review and network meta-analysis of stress-management interventions has been published (Webster 2025, PMID 40519356). Effect sizes are smaller than for sodium or DASH and blinding is impossible, so the evidence quality ceiling is low.

The durability problem

Almost everything above is measured in feeding studies, supervised programmes or intensively supported trials. Effects outside those conditions are smaller and decay. The exceptions are structural: salt substitution works because it changes what is in the salt cellar rather than what the person decides each day (Neal 2021, PMID 34459569), and population reformulation works for the same reason (McLaren 2016, PMID 27633834). This asymmetry — behaviour-dependent interventions decay, environment-dependent ones do not — is the most useful organising principle in this area and is under-exploited in guidelines.

Open questions

  • Is the observational J-curve for sodium real or a measurement artefact of spot-urine estimating equations plus reverse causation? Randomised evidence exists only for pressure, not for hard endpoints at low intake (O'Donnell 2014, PMID 25119607; Huang 2020, PMID 32094151).
  • Does salt substitution retain its benefit where most dietary sodium is embedded in processed food rather than added at home? The PubMed and ClinicalTrials.gov searches repeated on 2026-09-01 located no salt-substitution outcome trial in such a setting (Neal 2021, PMID 34459569; Yin 2022, PMID 35945000).
  • Is salt substitution safe in chronic kidney disease and in people on renin-angiotensin blockade plus mineralocorticoid receptor antagonists? Those groups were largely excluded (Brand 2022, PMID 35944931).
  • Why does potassium's pressure effect reverse at high supplementation in treated but not untreated hypertension? (Filippini 2020, PMID 32500831)
  • In DASH4D, sodium reduction contributed more than the dietary pattern. Does that generalise, and if so should dietary counselling be reordered? (Pilla 2025, PMID 40489102)
  • Exercise appears equivalent to drugs in hypertensive populations, but on only 56 trials with higher bias risk. Would an adequately powered exercise-versus-drug trial with a hard endpoint be feasible? (Naci 2019, PMID 30563873)

References

  1. Neal B, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385:1067-1077. PMID 34459569
  2. Huang L, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels. BMJ. 2020;368:m315. PMID 32094151
  3. Sacks FM, et al. Effects on blood pressure of reduced dietary sodium and the DASH diet. N Engl J Med. 2001;344:3-10. PMID 11136953
  4. Appel LJ, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-24. PMID 9099655
  5. O'Donnell M, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371:612-23. PMID 25119607
  6. Yin X, et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis. Heart. 2022;108:1608-1615. PMID 35945000
  7. Filippini T, et al. Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis. J Am Heart Assoc. 2020;9:e015719. PMID 32500831
  8. Roerecke M, et al. The effect of a reduction in alcohol consumption on blood pressure. Lancet Public Health. 2017;2:e108-e120. PMID 29253389
  9. Naci H, et al. How does exercise treatment compare with antihypertensive medications? Br J Sports Med. 2019;53:859-869. PMID 30563873
  10. Fu J, et al. Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension. J Am Heart Assoc. 2020;9:e016804. PMID 32975166
  11. Semlitsch T, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2021;2:CD008274. PMID 33555049
  12. He FJ, et al. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013;2013:CD004937. PMID 23633321
  13. He FJ, et al. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. J Hum Hypertens. 2002;16:761-70. PMID 12444537
  14. Huang L, et al. The impact of baseline potassium intake on the dose-response relation between sodium reduction and blood pressure change. J Hum Hypertens. 2021;35:946-957. PMID 33674705
  15. Mente A, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension. Lancet. 2016;388:465-75. PMID 27216139
  16. O'Donnell M, et al. Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality. BMJ. 2019;364:l772. PMID 30867146
  17. Liu X, et al. Associations of estimated 24-h urinary sodium excretion with mortality and cardiovascular events in Chinese adults. J Hypertens. 2021;39:484-493. PMID 33031177
  18. Kong F, et al. Dietary salt intake and cardiovascular outcomes: an umbrella review. Ann Med. 2025;57:2582065. PMID 41243115
  19. McLaren L, et al. Population-level interventions in government jurisdictions for dietary sodium reduction. Cochrane Database Syst Rev. 2016;9:CD010166. PMID 27633834
  20. Song J, et al. Impact of color-coded and warning nutrition labelling schemes: systematic review and network meta-analysis. PLoS Med. 2021;18:e1003765. PMID 34610024
  21. McMahon EJ, et al. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2021;6:CD010070. PMID 34164803
  22. Borrelli S, et al. Sodium Intake and Chronic Kidney Disease. Int J Mol Sci. 2020;21. PMID 32635265
  23. Huang L, et al. Interim effects of salt substitution on urinary electrolytes and blood pressure in SSaSS. Am Heart J. 2020;221:136-145. PMID 31986290
  24. Yu J, et al. Secondary Analysis of SSaSS: Effects of Potassium-Enriched Salt on Cardiac Outcomes. Hypertension. 2024;81:1031-1040. PMID 38465623
  25. Wang F, et al. Effect of salt substitution on fracture — secondary analysis of SSaSS. BMC Med. 2024;22:366. PMID 39232779
  26. Zhang X, et al. Effect of sodium-reduced potassium-enriched salt substitutes on stomach cancer: SSaSS. BMC Med. 2025;23:236. PMID 40264179
  27. Ding X, et al. Salt Substitution and Recurrent Stroke and Death: A Randomized Clinical Trial. JAMA Cardiol. 2025;10:343-350. PMID 39908026
  28. Tsai YC, et al. Effectiveness of salt substitute on cardiovascular outcomes. J Clin Hypertens. 2022;24:1147-1160. PMID 36196475
  29. Brand A, et al. Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health. Cochrane Database Syst Rev. 2022;8:CD015207. PMID 35944931
  30. Filippou CD, et al. DASH Diet and Blood Pressure Reduction in Adults with and without Hypertension. Adv Nutr. 2020;11:1150-1160. PMID 32330233
  31. Guo R, et al. Effects of the Modified DASH Diet on Adults With Elevated Blood Pressure or Hypertension. Front Nutr. 2021;8:725020. PMID 34557511
  32. Theodoridis X, et al. Adherence to the DASH Diet and Risk of Hypertension. Nutrients. 2023;15. PMID 37513679
  33. Pilla SJ, et al. Dietary Patterns, Sodium Reduction, and Blood Pressure in Type 2 Diabetes: The DASH4D Randomized Clinical Trial. JAMA Intern Med. 2025;185:937-946. PMID 40489102
  34. Filippou C, et al. DASH vs. Mediterranean diet on a salt restriction background. Clin Nutr. 2023;42:1807-1816. PMID 37625311
  35. Filippou C, et al. Overview of salt restriction in the DASH and Mediterranean diet. Rev Cardiovasc Med. 2022;23:36. PMID 35092228
  36. Rees K, et al. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev. 2013;2013:CD002128. PMID 24318424
  37. Whelton PK, et al. Effects of oral potassium on blood pressure. JAMA. 1997;277:1624-32. PMID 9168293
  38. Cappuccio FP, et al. Does potassium supplementation lower blood pressure? J Hypertens. 1991;9:465-73. PMID 1649867
  39. Filippini T, et al. The effect of potassium supplementation on blood pressure in hypertensive subjects. Int J Cardiol. 2017;230:127-135. PMID 28024910
  40. Binia A, et al. Daily potassium intake and sodium-to-potassium ratio in the reduction of blood pressure. J Hypertens. 2015;33:1509-20. PMID 26039623
  41. Granal M, et al. Effect of changes in potassium intake on blood pressure: a dose-response meta-analysis. Clin Kidney J. 2025;18:sfaf173. PMID 40612568
  42. Xin X, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38:1112-7. PMID 11711507
  43. Fuchs FD, et al. The Effect of Alcohol on Blood Pressure and Hypertension. Curr Hypertens Rep. 2021;23:42. PMID 34762198
  44. Cornelissen VA, et al. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004473. PMID 23525435
  45. Carlson DJ, et al. Isometric exercise training for blood pressure management. Mayo Clin Proc. 2014;89:327-34. PMID 24582191
  46. Baffour-Awuah B, et al. Isometric Resistance Training to Manage Hypertension. Curr Hypertens Rep. 2023;25:35-49. PMID 36853479
  47. Ansari HUH, et al. Efficacy and Safety of GLP-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters. Endocr Pract. 2024;30:160-171. PMID 38029929
  48. Yin Y, et al. Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters. J Diabetes. 2025;17:e70082. PMID 40207414
  49. Elmaleh-Sachs A, et al. Obesity Management in Adults: A Review. JAMA. 2023;330:2000-2015. PMID 38015216
  50. McGowan B, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31:3317-3329. PMID 41039116
  51. Ndumele CE, et al. 2026 AHA/ACC/ADA/ASN Guideline for Cardiovascular-Kidney-Metabolic Syndrome. J Am Coll Cardiol. 2026;87:e1889-e2007. PMID 42265997
  52. Webster KE, et al. Effectiveness of stress management and relaxation interventions for management of hypertension and prehypertension. BMJ Med. 2025;4:e001098. PMID 40519356